[Alpha 2-interferon in kidney cancer. Experiences with 6 patients].
We report on 6 male patients with advanced renal cell carcinoma without prior chemotherapy. They were treated by recombinant alpha 2-interferon in a toxicity limited dosage. The maximal tolerated dose was 3 x 5 x 10(6) U/wk. to 3 x 20 x 10(6) U/wk., limited by flu-like symptoms in 5 cases, by thrombopenia in 1. We observed a response in 3 cases (2 partial remissions, 1 mixed response) lasting for 10, 11 and 13 months, respectively. This comparatively good result may be due to patient characteristics (little pretreatment, pulmonary metastasis, good performance status) as well as to a medium dosage. Occurrence of response after termination of interferon therapy in two cases are of particular interest.
Weidmann
B
B
Zentrum für Innere Medizin, Städtisches Krankenhaus Leverkusen.
Hoffmann
W
W
Seeber
S
S
D002292:Carcinoma, Renal Cell / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins
Alpha 2-Interferon beim Nierenkarzinom: Erfahrungen an sechs Patienten.